MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.70
-0.52
-4.26%
After Hours: 11.70 0 0.00% 18:50 02/25 EST
OPEN
12.11
PREV CLOSE
12.22
HIGH
12.33
LOW
11.48
VOLUME
626.97K
TURNOVER
--
52 WEEK HIGH
14.62
52 WEEK LOW
1.480
MARKET CAP
544.05M
P/E (TTM)
-9.0132
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aldeyra Therapeutics (ALDX) Gets a Buy Rating from JonesTrading
JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Aldeyra Therapeutics (ALDX) today and set a price target of $20.00. The company's shares
SmarterAnalyst · 9h ago
What's in Store for Perrigo (PRGO) This Earnings Season?
Zacks.com · 6d ago
Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference at 3:40 p.m. ET Friday, February 26, 2021.
Business Wire · 02/18 13:00
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
Zacks.com · 02/17 18:28
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
Zacks.com · 02/17 14:31
DJ Aldeyra Therapeutics Price Target Announced at $26.00/Share by HC Wainwright & Co.
Dow Jones · 02/08 11:46
DJ Aldeyra Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 02/08 11:46
Analyst Actions: HC Wainwright Starts Aldeyra Therapeutics at Buy With $26 Price Target
MT Newswires · 02/08 07:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALDX stock price target is 25.27 with a high estimate of 32.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 155
Institutional Holdings: 24.34M
% Owned: 52.34%
Shares Outstanding: 46.50M
TypeInstitutionsShares
Increased
28
1.69M
New
36
-92.18K
Decreased
23
2.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Senior Vice President
James Gow
Senior Vice President
Stephen Machatha
Other
David McMullin
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Neal Walker
  • Dividends
  • Splits
  • Insider Activity
No Data
About ALDX
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.